Page 5 - Peter Lamb News Today

Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies using Ryvu’s STING technology

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential –ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and...

Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which

ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening

The Players’ Ring will close out the celebration of its 30th Season with one of Shakespeare’s most-loved comedies, A Midsummer Night’s Dream.

Mental Health Awareness 5K Walk Set for Friday

Peter Lamb and The Wolves, an energetic and engaging band out of the Triangle headlines the season’s final Come Sunday Jazz Brunch on Sunday, May 22, at Weymouth Center for

Exelixis, Inc. (NASDAQ:NASDAQ:EXEL) Q1 2022 Earnings Conference Call May 10, 2022, 05:00 PM ET Company Participants Susan Hubbard - EVP of Public Affairs and IR Mike Morrissey - President...

EXEL earnings call for the period ending March 31, 2022.